RE:RE:RE:Prior to the vote on the Vivo acquisition, managementQC, we have already seen tens of millions of shares churn through the LABS boiler the past couple years and the shareprice has concrete shoes, so I am not sure how many shares you are thinking in an NCIB to move the needle significantly, and not watch it settle back.
Buying back 25% of the float might leave these guys in a tight financial spot tight if all the potential irons take longer than expected.
I completely understand Medipharm shareholder frustration maybe more than most. as I took a major kick in the teeth with warrants I purchased during the last big PP, but leaving yourself exposed by buying back shares at this time is risky when the vultures are sitting in the tree tops.